Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
KALV 
Kalvista Pharmaceuticals Inc (KALV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: KALV (2-star) is a SELL. SELL since 1 days. Profits (16.01%). Updated daily EoD!
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit 92.68% | Avg. Invested days 35 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 554.58M USD | Price to earnings Ratio - | 1Y Target Price 26.33 |
Price to earnings Ratio - | 1Y Target Price 26.33 | ||
Volume (30-day avg) 626820 | Beta 0.76 | 52 Weeks Range 7.30 - 15.50 | Updated Date 04/2/2025 |
52 Weeks Range 7.30 - 15.50 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.77 |
Earnings Date
Report Date 2025-03-10 | When Before Market | Estimate -0.8678 | Actual -0.92 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -58.15% | Return on Equity (TTM) -150.5% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 307156919 | Price to Sales(TTM) 107.42 |
Enterprise Value 307156919 | Price to Sales(TTM) 107.42 | ||
Enterprise Value to Revenue 76.33 | Enterprise Value to EBITDA -3.53 | Shares Outstanding 49715600 | Shares Floating 29097070 |
Shares Outstanding 49715600 | Shares Floating 29097070 | ||
Percent Insiders 1.36 | Percent Institutions 113.45 |
Analyst Ratings
Rating 4.78 | Target Price 27.88 | Buy 2 | Strong Buy 7 |
Buy 2 | Strong Buy 7 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Kalvista Pharmaceuticals Inc
Company Overview
History and Background
KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing small molecule protease inhibitors to treat diseases with significant unmet needs. Founded to advance research on plasma kallikrein inhibitors, it has evolved through various clinical trials and strategic partnerships.
Core Business Areas
- Hereditary Angioedema (HAE): Focused on developing oral therapies for HAE, aiming to provide convenient and effective treatment options. This includes programs like KVD900, an oral kallikrein inhibitor for acute HAE attacks.
Leadership and Structure
Details about the leadership team and organizational structure not available without current real-time data.
Top Products and Market Share
Key Offerings
- KVD900 (Oral Plasma Kallikrein Inhibitor): An oral medication in development for acute HAE attacks. Market share data is currently unavailable as it is still in the development/approval phase. Competitors include injectable therapies such as Takhzyro (lanadelumab) from Takeda and Orladeyo (berotralstat) from BioCryst Pharmaceuticals.
Market Dynamics
Industry Overview
The market for HAE treatments is growing, driven by increased awareness and the development of novel therapies. The shift from injectable to oral therapies is a significant trend.
Positioning
KalVista aims to capture a significant share of the HAE acute treatment market by offering a convenient oral therapy. Their competitive advantage lies in oral availability.
Total Addressable Market (TAM)
The TAM for HAE therapies is estimated to be in the billions of dollars annually. KalVista's positioning is focused on capturing a portion of the acute treatment segment, estimated at several hundred million dollars based on existing injectable sales.
Upturn SWOT Analysis
Strengths
- Oral drug candidate for HAE acute attacks
- Strong intellectual property
- Experienced management team focused on rare diseases
Weaknesses
- Reliance on single product candidate (KVD900)
- Need for successful clinical trial outcomes
- Small company size relative to competitors
Opportunities
- Market expansion to new geographies
- Potential for label expansion to other indications
- Strategic partnerships or acquisition opportunities
Threats
- Competition from existing HAE therapies
- Regulatory hurdles and potential clinical trial failures
- Pricing pressures from payers
Competitors and Market Share
Key Competitors
- TAK
- BCRX
Competitive Landscape
KalVista's oral formulation aims to disrupt the market dominated by injectable therapies. The advantage lies in patient convenience, but success depends on efficacy and safety profile.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth is dependent on successful clinical development of KVD900.
Future Projections: Analyst estimates depend heavily on KVD900's clinical trial results and regulatory approval. Revenue projections would start upon commercialization.
Recent Initiatives: Focus on clinical development of KVD900 and advancing through clinical trials.
Summary
KalVista Pharmaceuticals is a company heavily reliant on the success of its lead candidate, KVD900. While the oral delivery offers a potential advantage over existing treatments, the company faces significant clinical and regulatory risks. Successful commercialization could drive substantial growth, but failure in clinical trials would severely impact the company's prospects. The market is competitive, requiring a differentiated profile to gain market share.
Similar Companies
BCRX
BioCryst Pharmaceuticals Inc
BCRX
BioCryst Pharmaceuticals Inc
TAK
Takeda Pharmaceutical Co Ltd ADR
TAK
Takeda Pharmaceutical Co Ltd ADR
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share estimates are approximate and based on publicly available data. Clinical trial outcomes are uncertain, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kalvista Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2015-04-09 | CEO & Director Mr. Benjamin L. Palleiko | ||
Sector Healthcare | Industry Biotechnology | Full time employees 150 | Website https://www.kalvista.com |
Full time employees 150 | Website https://www.kalvista.com | ||
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.